Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid
By Xcenda |
What are the implications to product access if Medicare utilized an Institute for Clinical and Economic Review (ICER)-based formulary? Xcenda experts examined several product classes to understand the beneficiary impact if patients were switched from a current treatment to a medicine ICER deemed high value.
Impact Analysis of ICER Formulary Implementation in Medicaid
For example, Xcenda research suggests that over 99 percent of prescriptions to treat MS would be switched from their current treatment to a medicine ICER deemed high value and that ¾ or more of prescriptions for medicines to treat RA, NSCLC, and psoriasis would have to be shifted to an ICER-recommended drug.
To learn more, download the report below.